Anatara Lifesciences Ltd (ANR) - Cash Flow Conversion Efficiency

Latest as of June 2025: -2.561x

Based on the latest financial reports, Anatara Lifesciences Ltd (ANR) has a cash flow conversion efficiency ratio of -2.561x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-1.37 Million ≈ $-971.13K USD) by net assets (AU$535.97K ≈ $379.23K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see ANR market cap overview for the company's overall valuation and market capitalisation.

Anatara Lifesciences Ltd - Cash Flow Conversion Efficiency Trend (2013–2025)

This chart illustrates how Anatara Lifesciences Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Anatara Lifesciences Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Anatara Lifesciences Ltd ranked by their cash flow conversion efficiency. Explore ANR cash flow quality index to measure how well operating cash flow supports reported net income.

Company Cash Flow Conversion Efficiency
Universe Pharmaceuticals Inc
NASDAQ:UPC
-0.136x
ETRUSCUS RESOURCES CORP.
F:ERR
-0.014x
RBR Group Ltd
AU:RBR
-2.148x
Yangaroo Inc
V:YOO
0.540x
Lazydays Holdings Inc
NASDAQ:GORV
0.889x
Triangle Energy (Global) Ltd
AU:TEG
3.581x
Presidio Property Trust
NASDAQ:SQFT
-0.038x
Reinhold Europe AB
WAR:RHD
0.023x

Annual Cash Flow Conversion Efficiency for Anatara Lifesciences Ltd (2013–2025)

The table below shows the annual cash flow conversion efficiency of Anatara Lifesciences Ltd from 2013 to 2025. View ANR stock price and chart for real-time trading data and today's change.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-06-30 AU$535.97K
≈ $379.23K
AU$-2.27 Million
≈ $-1.61 Million
-4.239x -363.73%
2024-06-30 AU$1.36 Million
≈ $965.52K
AU$-1.25 Million
≈ $-882.61K
-0.914x +62.57%
2023-06-30 AU$924.54K
≈ $654.17K
AU$-2.26 Million
≈ $-1.60 Million
-2.442x -49.22%
2022-06-30 AU$1.36 Million
≈ $965.33K
AU$-2.23 Million
≈ $-1.58 Million
-1.637x -198.86%
2021-06-30 AU$3.83 Million
≈ $2.71 Million
AU$-2.10 Million
≈ $-1.48 Million
-0.548x +42.59%
2020-06-30 AU$2.86 Million
≈ $2.02 Million
AU$-2.72 Million
≈ $-1.93 Million
-0.954x -152.17%
2019-06-30 AU$5.92 Million
≈ $4.19 Million
AU$-2.24 Million
≈ $-1.58 Million
-0.378x +2.02%
2018-06-30 AU$8.59 Million
≈ $6.08 Million
AU$-3.32 Million
≈ $-2.35 Million
-0.386x -61.22%
2017-06-30 AU$12.02 Million
≈ $8.51 Million
AU$-2.88 Million
≈ $-2.04 Million
-0.239x -1050.92%
2016-06-30 AU$13.48 Million
≈ $9.53 Million
AU$-280.37K
≈ $-198.38K
-0.021x +94.08%
2015-06-30 AU$5.48 Million
≈ $3.88 Million
AU$-1.92 Million
≈ $-1.36 Million
-0.351x -296.93%
2014-06-30 AU$7.23 Million
≈ $5.11 Million
AU$-639.27K
≈ $-452.32K
-0.088x -114.01%
2013-06-30 AU$-280.65K
≈ $-198.58K
AU$-177.22K
≈ $-125.39K
0.631x --

About Anatara Lifesciences Ltd

AU:ANR Australia Biotechnology
Market Cap
$1.57 Million
AU$2.23 Million AUD
Market Cap Rank
#30336 Global
#1774 in Australia
Share Price
AU$0.01
Change (1 day)
+0.00%
52-Week Range
AU$0.01 - AU$0.02
All Time High
AU$1.64
About

Anatara Lifesciences Ltd engages in the research, development, and commercialization of evidence-based solutions for gastrointestinal diseases in Australia. The company's products include Gastrointestinal ReProgramming, a multi-component, multi-coated medicine designed to address underlying factors associated with chronic gastrointestinal conditions, such as irritable bowel syndrome and inflammat… Read more